版本:
中国

BRIEF-Dynavax Technologies received anticipated requests for information from FDA review team in connection with pending BLA for HEPLISAV-B

Oct 3 Dynavax Technologies Corp

* Review team's questions are in line with company's expectations

* Working with FDA to resolve remaining questions in order to enable FDA to complete review by scheduled PDUFA action date of Dec 15

* Received anticipated requests for information from FDA review team in connection with pending BLA for HEPLISAV-B

* PDUFA action date of December 15, 2016 remains unchanged Source text: [bit.ly/2cX7rG8] Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐